Friday 27^th January 2017

13:30      Welcome and introduction (D. Betticher, Fribourg)

NSCLC, early and locally advanced disease, diagnosis, therapies (S. Peters, Lausanne)

13:35      Developments in radiotherapy for stage I-III NSCLC (D. De Ruysscher, Maastricht)

13:55      Surgical standards for mediastinal lymph nodes dissection: guidelines, realities, and prospects (P. van Schil, Antwerp)

14:15      Chemotherapy, targeted therapy and/or immunotherapy in stage III disease (D. Betticher, Fribourg)

14:35      Case presentations of locally advanced diseases, the role of chemotherapy/surgery vs radio-chemotherapy (P. van Schil, T. Krüger, S. Zimmermann, D. Betticher, D. De Ruysscher)

15:35      Current trial landscape in stage III incl. SAKK 16/14 / ETOP NICOLAS (S. Rothschild, Basel)

15:45      Coffee break

Biology and Pathology of lung cancer (R. Stahel, Zürich)

16:15      Advances in Pathology and Molecular Biology of NSCLC (L. Bubendorf, Basel)

16:45      The evolving field of EGFR and ALK inhibition: controversies (M. Edelman, Albuquerque)

17:15      Rare mutations in NSCLC and their treatments (O. Gautschi, Luzern)

Lung cancer screening (R.Stahel, Zürich)

17:45      Lung cancer screening - Pro (W. Weder, Zürich)

18:05      Lung cancer screening - Contra (L. Nicod, Lausanne)

18:25      Lung cancer screening - Discussion

18:30      Adjourn

Saturday 28^th January 2017

Immunotherapy (D. Betticher, Fribourg)

08:00      State of the art across thoracic malignancies (incl. case presentation) (S. Peters, Lausanne)

08:45      Immunotherapy, in combination, first or second line? (incl. case presentation) (E. Felip, Barcelona)

09:30      Coffee break

Oligometastatic disease (R. Stahel, Zürich)

10:00      Oligometastatic disease, in addition to systemic therapy

               - the role of surgery (P. van Schil, Antwerp)

               - the role of radiotherapy (D. De Ruysscher, Maastricht)

11:00      Case presentations of 3 difficult cases, in order that all the experts can report on their way to treat  (including liquid bioppsy, adjuvant therapies, etc) (A. Curioni, S. Rotschild, T. Krüger)

12:15      Wrap up (S. Peters, Lausanne)

12:20      End